Recurrent cardiotoxicity in a fluoropyrimidine treated cancer patient – case report and practical recommendations

Fluoropyrimidines remain some of the most used chemotherapeutics, despite the appearance in the therapeutic arsenal of targeted therapy and immunotherapy. Fluropyrimidines related cardiotoxicity is an undesirable adverse event and affects almost 20% of patients. The mechanisms of fluoropyrimidine to...

Descripción completa

Detalles Bibliográficos
Autores principales: Deac, Andrada Larisa, Pop, Raluca Maria, Crisan, Cristina Florina, Burz, Claudia Cristina, Buzoianu, Anca Dana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: UMF “Gr. T. Popa” Iasi Publishing House 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10194170/
https://www.ncbi.nlm.nih.gov/pubmed/37215066
http://dx.doi.org/10.22551/2023.39.1002.10241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10194170/
https://www.ncbi.nlm.nih.gov/pubmed/37215066
http://dx.doi.org/10.22551/2023.39.1002.10241

Ejemplares similares